Inside Labiotech 17 Aug 2023 Introducing Labiotech Newsletter 2.0 The readers have spoken, and we heard you! Throughout 2022 and the first half of 2023, we’ve been focusing our editorial efforts on a mix of short news pieces and longer reads. Despite a successful year in terms of readership (we broke the 195,000-reader mark in July!), our recent user survey told us that when […] August 17, 2023 - 2 minutesmins - By Joachim Eeckhout Share WhatsApp Twitter Linkedin Email
In Depth 15 Aug 2023 Can stem cell treatment repair damaged knees? Scientists’ fascination with amphibians like axolotls and newts, animals that are capable of scarlessly regrowing their limbs, sparked the idea of possibly replicating this in humans. Since 1958, when French oncologist Georges Mathe performed the first-ever stem cell transplantation – to save six nuclear researchers who were accidentally exposed to radiation – the technology has […] August 15, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Podcast 11 Aug 2023Beyond Biotech podcast 58 – Pepteins To learn about pepteins, we had a conversation with Christian Schwarz, CEO and co-founder of Numaferm. Numaferm is a German biotech company, specializing in the production of pepteins, which are an underdeveloped class of molecules located between peptides and proteins (with a length of 30-300 amino acids). Pepteins are non-structured and complex posing a […] August 11, 2023 Share WhatsApp Twitter Linkedin Email
In Depth 10 Aug 2023 Is Latin America becoming an investment hotspot for biotech and deep tech? Latin America has traditionally lagged behind in areas such as biotech and deep tech, but recently, it seems as though some countries in the region are starting to benefit from increasing investment in these areas. The reason Latin America has been slow to develop its biotech scene is largely due to the fact that government […] August 10, 2023 - 6 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 9 Aug 2023 Meet the startup working to help treat a rare pediatric cancer Nearly 50% of the children diagnosed with neuroblastoma are considered high-risk, where the tumor has spread, making surgery no longer a viable treatment option. Owing to this stark statistic, the disease is quite difficult to treat. But there might be light at the end of the tunnel. U.K.-based Renaissance Pharma’s drug candidate, which has shown […] August 9, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 8 Aug 2023 The patient perspective on clinical trials: what needs to change? In order to better understand clinical trials from a patient’s perspective and find out what they would ideally like to change throughout the trial process, a survey was launched earlier this year entitled “The Patient Perspective on Clinical Trials – What’s Going Well, What Needs to Change?”. In this article, we take a look at […] August 8, 2023 - 6 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Podcast 4 Aug 2023Beyond Biotech podcast 57: Group B Strep To recognize International Group B Strep Awareness Month in July, we had a conversation with MinervaX CEO, Per Fischer. MinervaX is a privately-held Danish biotechnology company developing a novel prophylactic vaccine against Group B streptococcus (GBS), with two phase II clinical trials ongoing in pregnant women and a phase I clinical trial ongoing in older adults. Due […] August 4, 2023 Share WhatsApp Twitter Linkedin Email
In Depth 3 Aug 2023 How is artificial intelligence rising to the challenge in breast cancer diagnosis? The scope of artificial intelligence (AI) in medicine has been rapidly expanding in recent years. With AI shaping the way clinical research is conducted, it has also opened doors for quicker drug discovery and diagnostic measures. And in the fight against breast cancer in particular, AI has emerged as a game-changer in digital pathology, revolutionizing […] August 3, 2023 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 2 Aug 2023 The biggest private biotech investments in July 2023 The companies Sinotau, Septerna, and Kriya Therapeutics bagged the biggest biotech investments in July 2023. Around the world, drug discovery and oncology attracted the biggest funding rounds. Biotech fundraising seemed to dry up a little bit in July 2023 compared to previous months, but that’s only to be expected as the summer kicks in. And, […] August 2, 2023 - 3 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 31 Jul 2023 Biogen acquiring Reata Pharmaceuticals for $7.3B Biogen Inc. and Reata Pharmaceuticals, Inc. have entered into a definitive agreement under which Biogen has agreed to acquire Reata for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3 billion. Reata has made advancements developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. Reata’s FDA-approved SKYCLARYS (omaveloxolone) is […] July 31, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 28 Jul 2023 Six companies driving Chennai’s biotech scene Just like Bangalore and Pune, the city of Chennai in the southern state of Tamil Nadu in India, is a key hub for the biotech industry in the country. Chennai, which runs AstraZeneca’s IT operations in the country at the Global Technology Centre, is home to over 50 biotech companies. Much of their focus lies […] July 28, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jul 2023 FDA grants breakthrough therapy designation to Duchenne muscular dystrophy treatment The U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy Designation to NS Pharma Inc.’s NS-089/NCNP-02, an investigational candidate for patients with Duchenne muscular dystrophy amenable to exon 44 skipping therapy. The breakthrough designation is based on results from a first-in-human, investigator-initiated clinical trial conducted in Japan. In June 2023, NS-089/NCNP-02 was granted Rare […] July 28, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email